Flibanserin
After previous denial, in 2015, the American Food and Drug Administration (FDA) approved flibanserin (brand name Addyi) for the treatment of low sexual desire in premenopausal women. Flibanserin has mixed effects on the serotonergic and dopaminergic neurotransmitter systems and was...